Abstract
Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid resistance among MRSA clinical isolates in our area. A very low prevalence of cfr mediated linezolid resistance was found: only one bacteremic isolate out of 2 215 screened isolates. The only linezolid resistant isolate arose in a patient, previously colonized by MRSA, following linezolid therapy. Despite the low rate of resistance in our area, ongoing surveillance is advisable to avoid the spread of linezolid resistance.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / therapeutic use*
-
Aged
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Proteins / metabolism*
-
Drug Resistance, Multiple, Bacterial
-
Hospitals
-
Humans
-
Linezolid
-
Male
-
Methicillin / therapeutic use
-
Methicillin-Resistant Staphylococcus aureus / drug effects*
-
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
-
Methicillin-Resistant Staphylococcus aureus / metabolism
-
Microbial Sensitivity Tests
-
Oxazolidinones / therapeutic use*
-
Spain
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
CFR protein, Staphylococcus aureus
-
Oxazolidinones
-
Linezolid
-
Methicillin
Grants and funding
This work was supported by a grant from Fondo de Investigación Sanitaria (grant number 10/01783) and by Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (grant number REIPI RD06/0008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.